|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/14 | |
| A61P 31/04 |
| (11) | Patento numeris | 2278989 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 09731140.1 |
| Europos patento paraiškos padavimo data | 2009-04-02 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-02-02 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-05-26 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2009/039240 |
| Data | 2009-04-02 |
| (87) | Numeris | WO 2009/126502 |
| Data | 2009-10-15 |
| (30) | Numeris | Data | Šalis |
| 43301 P | 2008-04-08 | US |
| (72) |
NEESHAM-GRENON, Eve, CA
MOECK, Gregory, CA
BELLEY, Adam, CA
PARR, Thomas, R. Jr, US
RAFAI FAR, Adel, CA
|
| (73) |
Melinta Therapeutics, Inc.,
44 Whippany Road Suite 280, Morristown, NJ 07960,
US
|
| (54) | ORITAVANCIN FOR INHIBITING AND TREATING BIOFILMS |
| ORITAVANCIN FOR INHIBITING AND TREATING BIOFILMS |